Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs > Inovio Pharmaceuticals, Inc. (INO)

Genetic Testing for Cancer

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
hlegweakreturns Member Profile
Followed By 1
Posts 447
Boards Moderated 0
Alias Born 07/31/13
160x600 placeholder
Inovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infectio... "GlobeNewswire Inc." - 4/21/2015 3:00:00 AM
3 Biotech Stocks That May Disappear Before 2020 "The Motley Fool" - 4/15/2015 8:59:03 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/13/2015 5:17:53 PM
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert "Seeking Alpha" - 4/9/2015 5:59:09 PM
Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress "GlobeNewswire Inc." - 4/9/2015 10:12:30 AM
Premarket Gainers / Losers as of 9:10 am "Seeking Alpha" - 4/9/2015 9:11:52 AM
Inovio Pharmaceuticals HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head & Neck Cancer Patients "GlobeNewswire Inc." - 4/9/2015 8:00:00 AM
Inovio Pharmaceuticals Selected by DARPA to Lead a $45 Million Program to Expedite Development of Novel Products to Prevent a... "GlobeNewswire Inc." - 4/8/2015 6:00:00 AM
Has the Biotech Bubble Already Popped? "The Motley Fool" - 4/4/2015 9:59:03 AM
5 Promising Biotech Stocks Under $10 "The Motley Fool" - 4/3/2015 8:04:02 AM
3 Biotechs That Could Change Medicine Forever: Wasatch Analyst Jill Wahleithner "Seeking Alpha" - 3/26/2015 6:01:11 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 3/20/2015 4:15:46 PM
Inovio Pharmaceuticals to Present at Alliance Regenerative Medicine's 2015 Regen Med Investor Day "GlobeNewswire Inc." - 3/19/2015 8:00:00 AM
Inovio Pharmaceuticals Appoints Scott M. White, M.D. Vice President, Clinical Development -- Infectious Diseases "GlobeNewswire Inc." - 3/18/2015 8:00:00 AM
Why Inovio Pharmaceuticals Inc. Shot Higher Today "The Motley Fool" - 3/16/2015 2:10:11 PM
Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infect... "GlobeNewswire Inc." - 3/16/2015 8:00:00 AM
Inovio Pharma ups revenues 47% in Q4 "Seeking Alpha" - 3/16/2015 7:50:58 AM
Annual Report (10-k) "Edgar (US Regulatory)" - 3/16/2015 7:24:34 AM
Inovio Pharmaceuticals misses by $0.02, misses on revenue "Seeking Alpha" - 3/16/2015 6:43:14 AM
Inovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results "GlobeNewswire Inc." - 3/16/2015 6:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/10/2015 4:40:32 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/9/2015 5:24:42 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/9/2015 5:21:43 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/9/2015 5:20:51 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 3/9/2015 4:18:21 PM
hlegweakreturns   Friday, 10/18/13 06:04:49 AM
Re: None
Post # of 12911 
Genetic Testing for Cancer
Is evolving very quickly and many folks are getting into the business. And there is more than one in New Jersey. Roche is entering this market, and they are not alone. Yesterday Bloomberg had an article on Quest entering the Breast-Cancer Test Market that is currently dominated by Myriad. I don't think Roche has any interest in Quest, but they obviously are looking for expanding their genetic diagnostic capability going forward, as evidenced by the PACB deal, and another agreement with a smaller, and interesting player in this market. So here is the article if you have any interest in tangential developments:

"Quest Diagnostics Inc. (DGX), the biggest U.S. operator of medical labs, began yesterday to sell a test for two breast cancer genes, providing competition for Myriad Genetics Inc. and potentially helping to reduce costs for women fearful they are at risk of the disease.Quest will sell the most comprehensive version of its test for the BRCA1 and BRCA2 genes for $2,500, said Richard Bender, a consultant for the Madison, New Jersey-based company. The price compares with almost $3,400 that Medicare pays for the most comprehensive version of a test from Myriad.

Myriad held a U.S. monopoly over the BRCA tests until June, when the U.S. Supreme Court invalidated parts of its gene patents. Immediately afterward, Ambry Genetics Corp. and another closely held company said they were entering the BRCA market. Quest is the largest competitor to move into the field. Quest’s test “will certainly be comparable to if not better than the data provided by Myriad” in its ability to identify a harmful mutation, Bender said by telephone.
Quest’s incursion into the BRCA testing market sets up a potential legal battle with Myriad, which has various remaining patents on its tests. “We feel we offer a test that is the gold standard in quality,” Ronald Rogers, a Myriad spokesman, said in a phone interview."

Quest’s test “does not violate any valid BRCA patent that Myriad Genetics may assert,” Wendy Bost, a Quest spokeswoman, said in an e-mail.
Quest said in an Oct. 10 complaint filed in federal court in Santa Ana, California, that it believes Myriad will bring a patent-infringement lawsuit if it starts selling its BRCA test products.
Myriad hasn’t yet been served with Quest’s complaint, said Rogers. “Once we receive that, we will read through it and weigh our options,” he said.
The case is Quest Diagnostics Inc. v. Myriad Genetics Inc. (MYGN), 13-cv-01587, U.S. District Court, Central District of California (Santa Ana).

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist